Haleon PLC Sponsored ADR (NYSE:HLN) Receives Average Rating of “Moderate Buy” from Analysts

Haleon PLC Sponsored ADR (NYSE:HLN) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and two have given a strong buy rating to the company.

HLN has been the subject of several recent analyst reports. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Friday, September 25th. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Wednesday, September 23rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th.

Institutional Trading of Haleon

Several institutional investors have recently modified their holdings of the stock. Western Wealth Management LLC purchased a new position in shares of Haleon in the 1st quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after acquiring an additional 2,404 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after acquiring an additional 1,055 shares in the last quarter. Fiduciary Financial Group LLC acquired a new position in Haleon in the second quarter valued at $97,000. Finally, Gryphon Financial Partners LLC acquired a new position in Haleon in the first quarter valued at $101,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.1%

NYSE HLN opened at $8.79 on Monday. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. Haleon has a 52 week low of $8.65 and a 52 week high of $11.28. The stock has a market capitalization of $38.68 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.99 and a beta of 0.14. The firm has a 50 day moving average of $9.65 and a two-hundred day moving average of $9.55.

Haleon Cuts Dividend

The business also recently declared a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were paid a $0.0642 dividend. This is a decrease from Haleon’s previous dividend of $0.1307. This represents a yield of 132.0%. The ex-dividend date was Friday, August 14th. Haleon’s payout ratio is currently 30.77%.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.